Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation
Laura Donadeu,Susana Gomez-Olles,Franc Casanova,Alba Torija,Manuel Lopez-Meseguer,Meritxell Boada-Pérez,Delphine Kervella,Elena Crespo,Claudia Carrera-Muñoz,Isabel Campos-Varela,Lluís Castells,Maria F. Cortese,Juliana Esperalba,Candela Fernández-Naval,Jesús Quintero,Marina Muñoz,Fernando Agüero,José Gonzalez-Costello,Laura Lladó,Alexandre Favà,Laura Cañas,María del Mar de la Hoz-Caballero,Maria Meneghini,Irina B. Torres,Mariona Juvé,FMJ Hafkamp,Marta Vila,Alba G. Robles,Maria José Buzón,Nestor Toapanta,José Miguel Zúñiga,Víctor Monforte,Berta Saez-Giménez,Oscar Len,Ibai Los Arcos,Enric Miret,Gema Ariceta,Emma Pardo,Xavier Martínez,Francesc Moreso,Oriol Bestard
DOI: https://doi.org/10.3389/fimmu.2024.1463769
IF: 7.3
2024-10-08
Frontiers in Immunology
Abstract:Introduction: Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear. Methods: We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination. Results: We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion. Discussion: Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients.
immunology